

SPONSOR SUBSTITUTE FOR HOUSE BILL NO. 37

IN THE LEGISLATURE OF THE STATE OF ALASKA

NINETEENTH LEGISLATURE - FIRST SESSION

BY REPRESENTATIVE B.DAVIS

Introduced: 2/22/95

Referred: Labor and Commerce, Health, Education and Social Services, Finance

A BILL

FOR AN ACT ENTITLED

1 "An Act relating to silicone implants; and providing for an effective date."

2 **BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF ALASKA:**

3 * **Section 1.** AS 08.64 is amended by adding new sections to article 3 to read:

4 Sec. 08.64.363. **REMOVAL OF BREAST IMPLANT.** A physician who
5 removes a breast implant shall send the breast implant to a laboratory for testing that
6 is approved by the Department of Health and Social Services. The laboratory shall
7 send the results of its test to the physician and to the department. The results are
8 confidential information, not subject to inspection or copying under AS 09.25.110 -
9 09.25.120.

10 Sec. 08.64.364. **PROHIBITION AGAINST SILICONE BREAST**
11 **IMPLANTATION.** A physician may not operate on a patient to insert a breast implant.
12 In this section, "breast implant" means a surgically inserted pocket or envelope under
13 the skin that consists of soft silicone gel, a combination of soft silicone gel and saline
14 solution, or silicone covered by polyurethane foam.

15 * **Sec. 2.** AS 08.64.364 is repealed and reenacted to read:

1 Sec. 08.64.364. BREAST IMPLANTATIONS. The board shall adopt
2 regulations necessary to ensure that physicians licensed under this chapter are required
3 to clearly and fully inform a patient who is considering a breast implant about the
4 advantages, disadvantages, and risks associated with the procedures and materials
5 involved. The board shall consider the informed consent requirements adopted by the
6 federal Food and Drug Administration when developing the regulations required under
7 this subsection. The board's regulations must require that the physician and the patient
8 sign a form that attests that the patient has received the information required under the
9 board's regulations before the physician may perform a breast implantation procedure
10 on the patient. The signed form shall be retained by the physician in the patient's
11 medical file. In this section, "breast implant" means a surgically inserted pocket or
12 envelope under the skin that consists of soft silicone gel, a combination of soft silicone
13 gel and saline solution, or silicone covered by polyurethane foam.

14 * **Sec. 3.** AS 18.05 is amended by adding a new section to read:

15 Sec. 18.05.048. BREAST IMPLANT REMOVALS; REGISTRY;
16 REGULATIONS. (a) The department shall maintain a registry of the

17 (1) names of patients from whom breast implants are removed;

18 (2) names of the patient's children who were born after the patient
19 received a breast implant if the patient is a woman; and

20 (3) test results received under AS 08.64.363.

21 (b) The commissioner shall adopt regulations regarding removed breast
22 implants, including regulations

23 (1) establishing a procedure to ensure confidentiality of information
24 obtained by the department in carrying out this section;

25 (2) governing the delivery and storage of removed breast implants;

26 (3) setting requirements for laboratory procedures for the testing and
27 storage of removed breast implants;

28 (4) establishing the types of test that must be performed on removed
29 breast implants;

30 (5) governing the compilation, evaluation, and disclosure of the test
31 results; and

1 (6) establishing a system for testing and monitoring the health of
2 patients who have received breast implants, patients from whom breast implants have
3 been removed, and the children of both groups of patients.

4 (c) In this section, "breast implant" means a surgically inserted pocket or
5 envelope under the skin that consists of soft silicone gel, a combination of soft silicone
6 gel and saline solution, or silicone covered by polyurethane foam.

7 * **Sec. 4.** AS 21.06 is amended by adding a new section to read:

8 Sec. 21.06.255. INFORMATION ABOUT COVERAGE OF BREAST
9 IMPLANTS. (a) An insurer authorized under AS 21.09 to offer, issue for delivery,
10 deliver, or renew an individual or group disability insurance policy for major medical
11 coverage on an expense incurred basis in the state, a hospital or medical service
12 corporation authorized under AS 21.87 to offer or renew a subscriber's contract, or a
13 health maintenance organization authorized under AS 21.86 to offer an enrollee
14 contract to provide health care services on a prepaid basis shall provide to the director
15 the following information in a form and manner, including frequency, determined by
16 the director under regulations that the director may adopt to implement this section:

17 (1) the coverage provided under the various plans of the insurer,
18 hospital or medical service corporation, or health maintenance organization for breast
19 implant removals and breast implant-related conditions; and

20 (2) the provisions of the various plans of the insurer, hospital or
21 medical service corporation, or health maintenance organization regarding preexisting
22 conditions for individuals with breast implants.

23 (b) Upon request of an individual, the director shall make available to the
24 individual the information received under (a) of this section. The director may include
25 a notice that the provision of the information does not mean that the director
26 guarantees the accuracy of the information.

27 (c) Failure to file the information required under (a) of this section is subject
28 to a civil penalty of \$100 for each day the failure continues.

29 (d) In this section, "breast implant" means a surgically inserted pocket or
30 envelope under the skin that consists of soft silicone gel or saline solution, a
31 combination of soft silicone gel and saline solution, or silicone covered by

1 polyurethane foam.

2 * **Sec. 5.** AS 21.42 is amended by adding a new section to read:

3 Sec. 21.42.377. BREAST IMPLANT COVERAGE. (a) An insurer authorized
4 under AS 21.09 to offer, issue for delivery, deliver, or renew an individual or group
5 disability insurance policy for major medical coverage on an expense incurred basis
6 in the state, a hospital or medical service corporation authorized under AS 21.87 to
7 offer or renew a subscriber's contract, or a health maintenance organization authorized
8 under AS 21.86 to offer an enrollee contract to provide health care services on a
9 prepaid basis may not refuse coverage, impose contract limitations, or require that the
10 insured, subscriber, or enrollee pay a higher deductible or copayment for the cost of
11 treating the insured, subscriber, or enrollee for the sole reason that the insured,
12 subscriber, or enrollee has a breast implant.

13 (b) In this section,

14 (1) "breast implant" means a surgically inserted pocket or envelope
15 under the skin that consists of soft silicone gel or saline solution, a combination of soft
16 silicone gel and saline solution, or silicone covered by polyurethane foam;

17 (2) "copayment" means the portion of the cost to be paid by the
18 insured, subscriber, or enrollee in excess of the deductible;

19 (3) "deductible" means the portion of covered costs that must be
20 incurred before benefits become payable;

21 (4) "major medical coverage" means a disability insurance contract, a
22 subscriber contract, or an enrollee contract that provides benefits for hospital and
23 medical care with potential lifetime maximum benefits for the insured or subscriber
24 of at least \$10,000.

25 * **Sec. 6.** TRANSITIONAL PROVISION. The first report required under AS 21.06.255,
26 enacted by sec. 4 of this Act, is due December 31, 1996.

27 * **Sec. 7.** Section 2 of this Act takes effect on the date the Food and Drug Administration
28 makes a final decision that confirms the safety and effectiveness of breast implants that
29 contain silicone. The commissioner of health and social services shall monitor the Food and
30 Drug Administration's activities in this area and immediately notify the revisor of statutes of
31 the date, if any, when the Food and Drug Administration makes the final decision described

1 in this section.